Pfizer Inc

NYSE: PFE
$28.93
-$0.29 (-1.0%)
Closing Price on October 21, 2024

PFE Articles

4/7 Wall St. reviews short interest in the higher-yield defensive dividend stocks for a sense of what short sellers may be thinking.
thinkstockAugust 26, 2014: Markets opened higher on Tuesday following a huge jump in durable goods orders, a better-than-expected report on consumer confidence, and a slowdown in home price...
ThinkstockBristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) had approved the drug ELIQUIS, as a treatment for Deep...
Jon OggInvestors seem to have grown accustomed to seeing the Dow Jones Industrial Average (DJIA) hitting new high after new high in 2014. Only the recent market volatility has created a situation...
thinkstockAugust 14, 2014: Markets opened higher on Thursday after a slightly worse-than-expected report on new claims for unemployment benefits.  U.S. export prices were higher in July and natural...
thinkstockAugust 12, 2014: Markets opened lower on Tuesday, took a brief turn into the green, and then settled into the red by mid-morning. Energy stocks led the decline as data on crude oil...
Jon OggThe short interest data is out for the July 31 settlement date. We often review the higher-yield defensive dividend stocks for a barometer of what short sellers may be thinking. The trends are...
These are the top analyst upgrades, downgrades and initiations from Wall Street analysts for Wednesday, August 6, 2014. They include Groupon, Micron, RingCentral, Target, Tesla, Monster and Pfizer.
The analysts at Jefferies have done some fine tuning to their Franchise Picks list, which is their cream-of-the-crop list. These stocks had the largest upside to the Jefferies designated price...
thinkstockJuly 29, 2014: Markets opened higher on Tuesday following a modestly better showing from companies reporting earnings before the opening bell. There was no major economic news today and...
U.S. Food & Drug AdministrationA purported herbal sexual health supplement called O.M.G. has been found by the U.S. Food and Drug Administration (FDA) to contain generic sildenafil, the...
Drug giants Merck and Pfizer reported better-than-expected second-quarter 2014 results before markets opened Tuesday morning.
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Monday, July 28, 2014. They include AcelRx Pharmaceuticals, Cisco Systems, Juniper Networks, Pfizer and Xerox.
Jon OggThe short interest data for the July 15 settlement date is out and we have compared the defensive dividend stocks, aside of utilities, to what has happened since the June 30 settlement date....
thinkstockJuly 21, 2014: Markets opened lower on Monday, stopping in its tracks the positive reversal we saw last Friday. There was no economic news today and the geopolitical news is dominated by...